Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers

There has been no report on whether the patients with colorectal cancer who are also inactive Hepatitis B Carriers should receive Prophylactic Use or preemptive Use of an Anti-viral Drug Entecavir. This open, randomized controlled clinical trial aims to compare the impact of the prophylactic use or preemptive use of an anti-viral drug Entecavir on the outcomes of patients with colorectal cancer who are also inactive hepatitis B carriers during chemotherapy and the subsequent follow-ups.

目前尚无针对同时为非活动性乙型肝炎病毒携带者（Hepatitis B Carrier）的结直肠癌患者，是否应采用抗病毒药物恩替卡韦（Entecavir）进行预防性用药或抢先治疗的相关研究报道。本项开放标签随机对照临床试验，旨在对比抗病毒药物恩替卡韦预防性给药与抢先给药方案，对上述患者在化疗期间及后续随访阶段的临床结局所产生的影响。